2017 • CEO
After leading and later selling Avila Therapeutics for $925 million to Celgene in 2012, KATRINE BOSLEY took over Editas Medicine in 2014 and led the company as it became the first ever publicly traded CRISPR-Cas9 drug developer. Soon after she came aboard, Bosley helped raise $120 million, a round that laid the groundwork for a $94 million IPO in 2016. Editas could possibly be the first U.S. company to test CRISPR-Cas9 drugs in humans next year.
Katrine Bosley, Editas Medicine • Photography by Alex Gagne and Rythum Vinoben